Clinical trials: MRD
CD19 Positive, B-ALL
Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia
The goal of this trial is to determine safe dosing of CD19-CD34t metabolically programmed CAR-T cell therapy in adult patients with CD19-positive B-cell acute lymphocytic leukemia (B-ALL).
- Conditions
- CD19 Positive, B-ALL, B-cell Acute Lymphocytic Leukemia, Chimeric Antigen Receptor T-cell
- Trial name
- NCT07896213
- Testing
- Fludarabine, Cyclophosphamide, Levetiracetam
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Light Chain (AL) Amyloidosis, MRD
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Before effective treatment, the prognosis of patients with AL amyloidosis is very poor, with a median survival of approximately 12 months.
- Trial name
- NCT07215494
- Testing
- First-Line Dara-BorCyD Treatment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University First Hospital
Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM.
- Conditions
- Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
- Trial name
- NCT06207799
- Testing
- Elranatamab, Lenalidomide, Plerixafor
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), NGS Monitor MRD
ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)
Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses among solid tumors. Even after curative-intent resection, 70-80% of patients recur within two years.
- Trial name
- K4CARE-PDAC (NCT07597252)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
MDS, SCT
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
This study aims to develop highly sensitive methods for early detection of relapse based on the patients unique mutations. Initially, a mutational screen is being performed.
- Conditions
- MDS, SCT, MRD
- Trial name
- NCT02872662
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 308 people
- Sponsor
- Nordic MDS Group
Molecular Surveillance, Breast Cancer
Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)
To learn about changes in ctDNA during the diagnosis, treatment, and post-treatment surveillance of EBC.
- Conditions
- Molecular Surveillance, Breast Cancer, ctDNA, MRD
- Trial name
- NCT07475923
- Testing
- Blood draw for the laboratory assessment, Neoadjuvant treatment
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
RGL-305+ Lymphoma + Exploratory Clinical Study
This study is an open, prospective, dose-increasing exploratory clinical trial. To evaluate the safety, cytodynamics and initial efficacy of RGL-305 in patients with lymphoma.
- Trial name
- NCT07006012
- Testing
- RGL-305
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
B ALL, Allogenetic Hematopoietic Stem Cell Transplantation
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
This prospective, open-label randomized controlled trial compares CD19 CAR-T therapy with chemotherapy plus donor lymphocyte infusion (DLI) in 70 patients with Ph-negative B-cell acute lymphoblastic leukemia (B-ALL) who exhibited…
- Conditions
- B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive
- Trial name
- NCT07441291
- Testing
- CAR-T, DLI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University People's Hospital
Esophageal Cancer, MRD
Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
Numerous studies have confirmed that ctDNA-MRD detection technology based on peripheral blood can identify minimal residual disease (MRD) following surgery and other curative treatments, indicating a higher risk of recurrence.
- Conditions
- Esophageal Cancer, MRD, ctDNA
- Trial name
- NCT07371247
- Testing
- Step-up therapy, Standard treatment Routine treatment
- Where
- China
- Volunteers
- 65 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
MRD, Prostate Cancer
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
- Conditions
- MRD, Prostate Cancer, mHSPC
- Trial name
- NCT07112612
- Volunteers
- 50 people
- Sponsor
- Anhui Medical University
NSCLC (Non-small Cell Lung Cancer), MRD
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
- Trial name
- CTONG 2508 (NCT07120698)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 115 people
- Sponsor
- Guangdong Association of Clinical Trials
Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.
- Trial name
- NCT07264010
- Testing
- Sorafenib (SORA), Venetoclax (VEN)
- Volunteers
- 87 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colorectal Cancer, MRD
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer.
- Conditions
- Colorectal Cancer, MRD, ctDNA
- Trial name
- NCT07254156
- Testing
- MRD detection
- Where
- China
- Volunteers
- 229 people
- Sponsor
- Sun Yat-sen University
Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients
Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia
The aim of this study is to test the potential benefit of an innovative combination of targeted therapy over the standard the immunochemotherapy (FCR).
- Conditions
- Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy
- Trial name
- ERADIC (NCT04010968)
- Testing
- venetoclax and ibrutinib (I+VEN), FCR
- Where
- 34 sites in France
- Volunteers
- 120 people
- Sponsor
- French Innovative Leukemia Organisation
ALL, MRD-positive
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
As part of postremission consolidative therapy, the decision to proceed with hematopoietic stem cell transplantation is a recommendable regimen in ALL therapy. However, The recurrence rate is high after transplantation.
- Conditions
- ALL, MRD-positive, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT05940961
- Testing
- Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sheng-Li Xue, MD
Acute Leukemia, Acute Myeloid Leukemia
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT02722668
- Testing
- Fludarabine, Cyclophosphamide, MMF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD)
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
This is a research study to find out if a drug called blinatumomab is effective for treating patients with relapsed or refractory (R/R) or measurable residual disease (MRD) CD19-positive mixed phenotypic acute leukemia (MPAL).
- Trial name
- NCT04827745
- Testing
- BLINCYTO (Blinatumomab)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Maryland, Baltimore
Newly Diagnosed, High Risk
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
The goal of this study is to evaluate sustained MRD negativity for one year in DKRD induction \& consolidation therapy +/- ASCT in newly diagnosed high-risk multiple myeloma patients.
- Conditions
- Newly Diagnosed, High Risk, MRD, Multiple Myeloma
- Trial name
- NCT06409702
- Testing
- Carfilzomib, Daratumumab, Lenalidomide
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Breast Cancer, MRD
Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
This is an observational clinical study of MRD as a predictor of local treatment in patients with oligometastatic breast cancer.
- Trial name
- NCT06918262
- Testing
- local treatment
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University